Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

26.98 +0.45 (+1.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Via The Motley Fool
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?
Via The Motley Fool
2 Disruptive Growth Stocks With Room to Run
Via The Motley Fool
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Analysts are concerned about Viking's ability to compete in the lucrative obesity drug market, dominated by Eli Lilly and Novo Nordisk. 
Via Benzinga
How Is The Market Feeling About Viking Therapeutics?
 
Via Benzinga
Is It Too Late to Buy Viking Therapeutics Stock?
Via The Motley Fool
Market Whales and Their Recent Bets on VKTX Options
 
Via Benzinga
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow
Via The Motley Fool
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis. 
Via Benzinga
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
Via Investor's Business Daily
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH resolution, and fibrosis improvement. 
Via Benzinga
Money In Motion: Top Picks To Power Your Portfolio Today
Top stocks set to dominate the market today. 
Via Talk Markets
3 Things You Need to Know if You Buy Viking Therapeutics Today
Via The Motley Fool
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Mergers and acquisitions could make a comeback with Trump headed back to Washington. 
Via The Motley Fool
Topics Government
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry. 
Via The Motley Fool
Is Viking Therapeutics a Buy on the Dip?
Viking stock has slipped more than 20% from its peak. 
Via The Motley Fool
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
All signs are pointing toward its continued success. 
Via The Motley Fool
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
The company's latest presentation supports the idea that its lead program will make billions. 
Via The Motley Fool
Is Viking Therepautics a Buy Now?
The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales. 
Via The Motley Fool
Why Viking Therapeutics Stock Plummeted After Soaring Today
Are we ready for the Great Obesity Drug Gold Rush of the 2020s? 
Via The Motley Fool
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and improved prediabetic outcomes. 
Via Benzinga
Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data
The biotech reported strong weight loss for higher doses of its experimental obesity pill. 
Via Investor's Business Daily
MarketBeat Week in Review – 10/28 - 11/1
Stocks staged a strong rally on Friday following a steep sell-off; a weak jobs report all but guarantees a rate cut which adds to bullish sentiment 
Via MarketBeat
Topics Artificial Intelligence Economy
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.